Document:

<PAGE>   1
                                                                   EXHIBIT 10.25

                                NEORX CORPORATION
                   NONQUALIFIED STOCK OPTION LETTER AGREEMENT
                                NOVEMBER 16, 2000

TO:  DOUGLASS GIVEN

We are pleased to inform you that you have been granted a nonqualified stock
option under the NeoRx Corporation Restated 1994 Stock Option Plan (the "Plan")
for the purchase of 100,000 shares of NeoRx Corporation's (the "Company") common
stock at an exercise price of $9.1875 per share, pursuant to the terms and
conditions set forth below and in the Company Plan. A copy of the Plan is
attached and incorporated into this Agreement by reference.

The terms of the option are as set forth in the Plan and in this Agreement. The
most important of the terms set forth in the Plan are summarized as follows:

               DATE OF GRANT: The date of grant of the option is November 15,
2000.

               VESTING: The option shall vest and become exercisable, subject to
shareholder approval of the Plan, in accordance with the following schedule:

<TABLE>
<CAPTION>
                 Date On and After Which                    Portion of Total Option
                  Option is Exercisable                       Which is Exercisable
                  ---------------------                     -----------------------
<S>                                                          <C>
                    November 15, 2000                                 25%
                      May 15, 2001                                    50%
                    November 15, 2001                                 75%
                      May 15, 2002                                   100%
</TABLE>

               TERM: The option will expire upon the earlier of ten years from
the date of grant or two years after your termination of service as a Consultant
to the Company, unless sooner terminated.

               EXERCISE: During your lifetime only you can exercise the option.
The Plan also provides for exercise of the option by the personal representative
of your estate or the beneficiary thereof following your death.

               PAYMENT FOR SHARES: The option may be exercised by the delivery
of:

               (1) Cash, personal check (unless, at the time of exercise, the
Plan Administrator determines otherwise), bank certified or cashiers check;

               (2) Unless the Plan Administrator in its sole discretion
determines otherwise, shares of the capital stock of the Company held by you for
a period of at least six months having a fair market value at the time of
exercise, as determined in good faith by the Plan Administrator, equal to the
exercise price; or

<PAGE>   2
               (3) A properly executed exercise notice together with irrevocable
instructions to a broker to promptly deliver to the Company the amount of sale
or loan proceeds to pay the exercise price.

               TERMINATION: If you cease to be a Consultant to the Company for
any reason other than death or termination for cause, and unless by its terms
this option sooner terminates or expires, then you may exercise, for a two-year
period, that portion of your option which is exercisable at the time of such
cessation, but the option shall terminate at the end of such period following
such cessation as to all shares for which it has not theretofore been exercised.

               DEATH OF OPTIONEE: If you die while serving as a Consultant to
the Company or within the two-year period following cessation of such service,
this option may, to the extent that you would have been entitled to exercise
this option, be exercised within one year after your death by the personal
representative of your estate or by the person or persons to whom your rights
under this option shall pass by will or by the applicable laws of descent and
distribution, unless sooner terminated.

               STATUS OF SHAREHOLDER: Neither you nor any person or persons to
whom your rights and privileges under this option may pass shall be, or have any
of the rights or privileges of, a shareholder of the Company with respect to any
of the shares issuable upon the exercise of this option unless and until this
option has been exercised.

               CONTINUATION OF STATUS AS CONSULTANT: Nothing in this Agreement
shall confer upon you any right to continue as a Consultant to the Company, or
to interfere in any way with the right of the Company to terminate your service
as a Consultant to the Company at any time.

               TRANSFER OF OPTION: This option and the rights and privileges
conferred hereby may not be transferred, assigned, pledged or hypothecated in
any manner (whether by operation of law or otherwise) other than by will, by the
applicable laws of descent and distribution, and shall not be subject to
execution, attachment or similar process. Any attempt to transfer, assign,
pledge, hypothecate or otherwise dispose of this option or of any right or
privilege conferred hereby, contrary to law or to the provisions of this
Agreement, or the sale or levy or any attachment or similar process upon the
rights and privileges conferred hereby shall be null and void.

               HOLDING PERIOD: Shares of common stock obtained upon the exercise
of this option may not be sold until six months after the date the option was
granted.

               Your particular attention is directed to the section(s) of the
Plan which describe(s) certain important conditions relating to federal and
state securities laws that must be satisfied before the option can be exercised
and before the company can issue any shares to you. The Company intends to
maintain an effective registration statement with respect to the shares that
will be issued upon exercise of this option but has no obligation to do so. If
there is no effective registration statement, you will not be able to exercise
the option or sell the option shares unless exemptions from registration under
federal and state securities laws are available. Such exemptions are very
limited and might be unavailable. Consequently, you might have no opportunity to
exercise the option and to receive shares upon such exercise.
<PAGE>   3
               Please execute the Acceptance and Acknowledgment set forth below
and return it to the undersigned.

NEORX CORPORATION

---------------------------------
PAUL G. ABRAMS
CHIEF EXECUTIVE OFFICER

                          ACCEPTANCE AND ACKNOWLEDGMENT

I, Douglass Given, a resident of the State of California, accept the
nonqualified stock option described above and in NeoRx Corporation's 1994 Stock
Option Plan, and acknowledge receipt of a copy of this Agreement, including a
copy of the Plan. I have read and understand the Plan, including the
provision(s) relating to federal and securities law.

               Dated:
                     -----------------------            ------------------------

---------------------
Taxpayer I.D. Number

By signing below, the spouse of the Optionee, if such Optionee is legally
married as of the date of execution of this Agreement, acknowledges that (s)he
has read this Agreement and the Plan and is familiar with the terms and
provisions thereof, and agrees to be bound by all the terms and conditions of
this Agreement and the Plan.

               Dated:
                     -----------------------            ------------------------

By signing below, the Optionee represents that (s)he is not legally married as
of the date of execution of this Agreement.

               Dated:
                     -----------------------            ------------------------<PAGE>   1
                                                                   EXHIBIT 10.37

                            ISV-900 PROJECT AGREEMENT
                             TERMINATION AND RELEASE

     This ISV-900 PROJECT AGREEMENT TERMINATION AND RELEASE ("Termination and
Release") is made as of December 10, 2000, by and between PHARMACIA & UPJOHN AB,
a Swedish corporation ("P&U "), and INSITE VISION INCORPORATED, a Delaware
corporation ("InSite"). InSite and P&U may be referred to herein individually as
a "Party" or collectively as the "Parties."

                                    RECITALS

     WHEREAS, InSite and P&U entered into the ISV-900 Project Agreement on
November 11, 1999 (the "ISV-900 Project Agreement");

     WHEREAS, the Parties desire to terminate the ISV-900 Project Agreement and
the rights and obligations of the Parties thereunder in accordance with the
terms hereof; and

     WHEREAS, contemporaneously with the execution of this Termination and
Release, InSite and Pharmacia & Upjohn Company, an Affiliate of P&U, are
terminating the Credit Agreement dated November 11, 1999 by and between such
parties (the "Credit Agreement").

     NOW THEREFORE, in consideration of the covenants and promises in this
Termination and Release, InSite and P&U agree as follows:

                                   ARTICLE I.
                  TERMINATION OF THE ISV-900 PROJECT AGREEMENT

     SECTION 1.1 DEFINITIONS. For purposes of this Termination and Release, the
initially capitalized terms used herein without definition shall have the
meanings ascribed thereto in the ISV-900 Project Agreement, whether used in the
singular or plural. The use of defined terms from the ISV-900 Project Agreement
is solely for administrative convenience and shall not, in and of itself, be
construed as implying any part of the ISV-900 Project Agreement continues beyond
termination, except as specifically set forth herein.

<PAGE>   2

     SECTION 1.2 TERMINATION. The Parties hereby terminate the ISV-900 Project
Agreement. Such termination is made mutually by the Parties without reference to
any specific provision of the ISV-900 Project Agreement. Subject to the terms
and conditions hereof and notwithstanding anything contained in the ISV-900
Project Agreement to the contrary, InSite and P&U hereby agree that all of the
rights and obligations of either or both of the Parties under the ISV-900
Project Agreement of whatever nature are hereby terminated, except as expressly
set forth herein. The Parties further agree that all rights and obligations
relating to the ISV 900 project or their activities under the ISV-900 Project
Agreement shall be governed solely and exclusively by this Termination and
Release.

     SECTION 1.3 RELEASE. In connection with the termination of the ISV-900
Project Agreement, and notwithstanding anything contained in the ISV-900 Project
Agreement to the contrary, including without limitation Section 11.5(a) of such
agreement, each Party hereby fully and forever releases and discharges the other
Party and its Affiliates and each of their respective shareholders, employees,
officers and directors from any and all claims, actions, losses, damages,
liabilities, costs and expenses of any kind or nature arising out of or related
to the ISV-900 Project Agreement, the Parties' performance or failure to perform
under or interactions pursuant to such agreement, or the termination of such
agreement, whether known or unknown and whether arising in the past, present or
future and hereby expressly waive any and all rights available to P&U and InSite
under Section 1542 of the California Civil Code, or any analogous state, federal
or foreign statutes, rules and regulations. Section 1542 of the Civil Code of
the State of California reads as follows:

     A general release does not extend to claims which the creditor does not
     know or suspect to exist in his favor at the time of executing the release,
     which, if known by him, must have materially affected his settlement with
     the debtor.

     The provisions of this Section 1.3 shall not apply to any losses, damages,
liabilities, costs and expenses for which a Party is entitled to indemnification
pursuant to Sections 5.2 or 5.3, as the case may be, of this Termination and
Release.

     SECTION 1.4 EXPRESS TERMINATION OF LICENSES AND RELATED OBLIGATIONS. For
purposes of emphasis and not limitation, the Parties acknowledge and agree that
(a) all licenses and rights granted by InSite under Article II of the ISV-900
Project Agreement and all of InSite's obligations under Article II, are
terminated and are of no further orce or effect, and (b) InSite shall retain all
of its right, title and interest in and to (i) its rights under the ISV-900
Agreements, ISV-900 Technology, and Trademarks; and any of its Improvements to
the foregoing.

     SECTION 1.5 DEVELOPMENT INFORMATION AND KNOW-HOW. Notwithstanding anything
contained herein to the contrary, P&U shall continue to own and have the
exclusive right, title and interest in all Know-How of P&U resulting or arising
from any development by P&U.

     SECTION 1.6 KNOW-HOW. Whereas in Section 2.1(b) if the ISV-900 Project
Agreement, InSite assigned to P&U all of InSite's right title, and interest in
the InSite Know-How, P&U hereby assigns back to InSite all such right title, and
interest in the InSite Know-How.

                                       2
<PAGE>   3

     SECTION 1.7 TERMINATION OF INSITE'S ROYALTY OBLIGATION. For purposes of
emphasis and not limitation, the Parties acknowledge that pursuant to the
provisions of Section 1.2 of this Termination and Release, the provisions of
Section 11.5(d) of the ISV-900 Project Agreement wherein P&U would otherwise be
entitled to a fifteen percent (15%) royalty on all net sales of Product
following a termination of the ISV-900 Project Agreement shall not be operative
or effective and P&U hereby waives all rights to any such royalty.

                                  ARTICLE II.
                       EXPRESS TERMINATION OF ARTICLE III

     SECTION 2.1 EXPRESS TERMINATION OF PAYMENT OBLIGATIONS. For purposes of
emphasis and not limitation, the Parties acknowledge and agree that pursuant to
Section 1.2 of this Termination and Release, the following specific provisions
of the ISV-900 Project Agreement are terminated and of no force or effect.

          (a)  All obligations under Section 3.2 of the ISV-900 Project
     Agreement with respect to any R&D Payments payable by P&U to InSite are
     terminated, including the Two Million Dollars ($2,000,000) payable on July
     1, 2001 and the One Million Dollars ($1,000,000) payable on July 1, 2002.

          (b)  All obligations of P&U under Section 3.3 with respect to any and
     all Milestone Payments are hereby terminated, including the First Milestone
     of One Million Five Hundred Thousand Dollars ($1,500,000) and the Second
     Milestone of One Million Five Hundred Thousand Dollars ($1,500,000). The
     Parties expressly agree that neither the Development Committee nor the
     Executive Committee has made or will make any decision regarding whether
     the First Milestone or Second Milestone has been achieved.

          (c)  All obligations of P&U under Section 3.4 with respect to the
     payment of any and all Royalties are terminated.

     SECTION 2.2 P&U acknowledges and agrees that this Termination and Release
does not require, and InSite shall not be obligated to make, any refund or
restitution of any amounts paid by P&U to InSite, or committed by P&U to third
parties, through the termination date of the ISV-900 Project Agreement.

                                  ARTICLE III.
                                   COMMITTEES

     SECTION 3.1 DEVELOPMENT AND EXECUTIVE COMMITTEES.

          (a)  Within ten (10) Business Days after the date hereof the
     Development Committee shall begin the process of winding down the ISV-900
     project. During the wind-down phase, which phase shall last for sixty (60)
     days from the date hereof, the Development Committee shall continue to
     operate consistent with the procedures set forth in the ISV-900 Project
     Agreement. Sixty (60) days after the date hereof, the

                                       3
<PAGE>   4

     Development Committee shall have no further responsibilities with respect
     to the ISV-900 project.

          (b)  The Executive Committee shall decide any matters referred to it
     by the Development Committee during the wind down period pursuant to the
     procedures set forth in the ISV-900 Project Agreement. Sixty (60) days
     after the date hereof, the Executive Committee shall have no further
     responsibilities with respect to the ISV-900 project.

          (c)  Such wind-down activities shall include, the return by each Party
     of the Confidential Information of the other Party.

                                  ARTICLE IV.
                          CREDIT AGREEMENT TERMINATION

     SECTION 4.1 CREDIT AGREEMENT. The Parties hereby acknowledge that,
contemporaneously herewith, and as a condition to the effectiveness hereof, the
Credit Agreement whereby Pharmacia & Upjohn Company agreed to make available to
InSite up to Four Million Dollars ($4,000,000) in debt financing on the second
anniversary of the Effective Date is being terminated pursuant to that certain
Credit Agreement Termination and Release of even date herewith (the "Credit
Agreement Termination").

                                   ARTICLE V.
                        CONTINUING RIGHTS AND OBLIGATIONS

     SECTION 5.1 INDEMNIFICATION BY INSITE. InSite shall indemnify and hold
harmless P&U, P&U's Affiliates and each of their respective officers, directors,
agents and employees (collectively, the "P&U Indemnitees") from and against all
losses, damages, costs, expenses (including court costs and legal fees on a full
indemnity basis) or other liabilities net of any tax benefit ("Liabilities")
incurred by any of the P&U Indemnitees as a result of any third party claims,
demands, suits or actions arising out of or related to (i) the breach of any
representation or warranty originally made by Insite in the ISV-900 Project
Agreement, or (ii) the development of ISV 900 and/or commercialization of the
Product.

     SECTION 5.2 INDEMNIFICATION BY P&U. P&U shall indemnify and hold harmless
InSite, InSite's Affiliates and each of their respective officers, directors,
agents and employees (collectively, the "InSite Indemnitees") from and against
all Liabilities incurred by any of the InSite Indemnitees as a result of any
third party claims, demands, suits or actions arising out of or related to (i)
the breach of any representation or warranty originally made by P&U in the
ISV-900 Project Agreement or (ii) P&U's exercise or exploitation of P&U's
Know-How.

     SECTION 5.3 INDEMNIFICATION PROCEDURES.

          (a)  A Party entitled to indemnification hereunder for third party
     claims (the "Indemnitee") that intends to claim indemnification under this
     Article 5 shall: (i) notify

                                       4
<PAGE>   5

     the other Party (the "Indemnitor") of any Liability with respect to which
     the Indemnitee intends to claim indemnification as soon as practicable
     after the Indemnitee becomes aware of any such Liability; (ii) permit the
     Indemnitor to assume the defense thereof with counsel mutually satisfactory
     to the Indemnitee and Indemnitor; and (iii) cooperate with the Indemnitor,
     at the Indemnitor's expense, in the defense thereof.

          (b)  With respect to any matter for which the Indemnitor may have an
     obligation to indemnify the Indemnitee under this Agreement, the Indemnitee
     shall have the right to participate and be represented (at the Indemnitor's
     expense) by legal counsel of the Indemnitee's choice in all proceedings and
     negotiations, if representation by counsel retained by Indemnitor would be
     inappropriate due to actual or potential differing interests between the
     Indemnitee and any other Party represented by such counsel in such
     proceedings.

          (c)  The indemnity agreement in this Article 5 shall not apply to
     amounts paid in settlement of any Liability if such settlement is effected
     without the consent of the Indemnitor, which consent shall not be
     unreasonably withheld.

          (d)  Failure of the Indemnitee to deliver notice to the Indemnitor
     within a reasonable time after becoming aware of a Liability shall relieve
     the Indemnitor of any liability to the Indemnitee pursuant to this Article
     5 in the event, but only to the extent, such delay is prejudicial to the
     Indemnitor's ability to defend such action.

          (e)  It is understood and agreed that the indemnification provisions
     of Article IX of the ISV-900 Project Agreement have been terminated
     pursuant to the provisions of Section 1.2 of this Termination and Release
     and that the indemnification provisions set forth herein shall supersede in
     all respects the provisions of Article IX of the ISV-900 Project Agreement.

                                  ARTICLE VI.
                                 CONFIDENTIALITY

     SECTION 6.1 CONFIDENTIAL INFORMATION. All data, information, documents and
materials transmitted by one Party (the "Disclosing Party") to the other Party
(the "Receiving Party") in connection with the ISV-900 Project Agreement or this
Termination and Release, including, but not limited to, all Know-How, clinical
data, information reports, financial or business records, summaries and
information gathered, generated or transferred by the Disclosing Party to the
Receiving Party during the course thereof and hereof shall remain confidential
and proprietary information (hereinafter "Confidential Information").

     SECTION 6.2 DISCLOSURE. The Receiving Party shall not disclose, without
prior written consent of the Disclosing Party, any Confidential Information to
any Third Party other than officers, directors, Affiliates and representatives
of the receiving Party, except as necessary to carry out its obligations under
this Termination and Release. Moreover, the Receiving Party shall not use the
Confidential Information of the Disclosing Party for any purpose whatsoever,
other than in carrying out its obligations under this Termination and Release,
without the prior

                                       5
<PAGE>   6

     written consent of the Disclosing Party. This Article 6 shall not apply to
     information which is (a) independently developed by the disclosing Party as
     shown by contemporaneous records, (b) is provided to the disclosing Party
     by a third party with the lawful right to disclose such information or (c)
     required to be disclosed by any valid law or regulation.

     SECTION 6.3 SURVIVAL. The obligations of the Parties with regard to
Confidential Information shall be in effect throughout the Territory and shall
continue in full force and effect for a period of five (5) years from the date
hereof.

                                  ARTICLE VII.
                                  MISCELLANEOUS

     SECTION 7.1 NOTICE. Except as otherwise specifically provided herein, any
notice or other documents to be given under this Termination and Release shall
be in writing and shall be deemed to have been duly given if sent by registered
post, nationally recognized overnight courier or facsimile transmission to a
Party or delivered in person to a Party at the address or facsimile number set
out below for such Party or such other address as the Party may from time to
time designate by written notice to the other:

          If to P&U:

          Pharmacia & Upjohn AB
          C/o Pharmacia & Upjohn Company
          100 Route 206 North
          Peapack, New Jersey 07977
          Attn:  Vice President, Associate General Counsel and
                 Corporate Secretary
          Telefax:  908-901-1862

          With required copy to:

          Pharmacia & Upjohn Company
          100 Route 206 North
          Peapack, New Jersey 07977
          Attn:  Senior Vice President, Corporate Licensing
          Telefax:  908-901-1813

          Pharmacia & Upjohn AB
          Lindhagensgatan 133
          112 87 Stockholm, Sweden
          Attn:  VP and Associate General Counsel, Europe & International
          Telefax:  011-46-8-695-4708

                                       6
<PAGE>   7

          If to InSite:

          InSite Vision Incorporated
          965 Atlantic Avenue
          Alameda, California 94501
          Attn:  Chief Executive Officer
          Telefax:  510-865-7830

          With required copy to:

          Brobeck, Phleger & Harrison LLP
          Two Embarcadero Place
          2200 Geng Road
          Palo Alto, CA  94303
          Attn:  Timothy R. Curry, Esq.
          Telefax:  (650) 496-2885

Any such notice or other document shall be deemed to have been received by the
addressee three (3) Business Days following the date of dispatch of the notice
or other document by post or, where the notice or other document is sent by
overnight courier, by hand or is given by facsimile, simultaneously with the
transmission or delivery. To prove the giving of a notice or other document it
shall be sufficient to show that it was dispatched.

     SECTION 7.2 ENTIRE AGREEMENT. This Termination and Release and the Credit
Agreement Termination embody and set forth the entire agreement and
understanding of the Parties with respect to the subject matter herein and
therein. There are no promises, terms, conditions or obligations, oral or
written, expressed or implied, other than those contained in such documents with
respect to the subject matter herein and therein.

     SECTION 7.3 HEADINGS, INTERPRETATION. The headings used in this Termination
and Release are for convenience only and are not a part of this Termination and
Release nor shall they affect the interpretation of any of its provisions.

     SECTION 7.4 GOVERNING LAW. This Termination and Release shall be governed
by and construed under the laws of the State of New York, excluding its conflict
of laws principles. The parties agree to submit to the exclusive jurisdiction of
New York courts to resolve any controversy.

     SECTION 7.5 SEVERABILITY. In the event that any provision of this
Termination and Release or the application thereof to any Party or circumstance
shall be finally determined by a court of proper jurisdiction to be invalid or
unenforceable to any extent, then (i) a suitable and equitable provision shall
be substituted therefore in order to carry out, so far as may be valid and
enforceable, the intent and purpose of such invalid and unenforceable provision
and (ii) the remainder of this Termination and Release and the application of
such provision to the Parties or circumstances other than those to which it is
held invalid or unenforceable shall not be affected thereby.

                                       7
<PAGE>   8

     SECTION 7.6 INTERPRETATION. The Parties hereto acknowledge and agree that
(i) each Party and its representatives has reviewed and negotiated the terms and
provisions of this Termination and Release and have contributed to its revision,
(ii) the rule of construction to the effect that any ambiguities are resolved
against the drafting Party shall not be employed in the interpretation of this
Termination and Release and (iii) the terms and provisions of this Termination
and Release shall be construed fairly as to each Party hereto and not in favor
of or against either Party regardless of which Party was generally responsible
for the preparation of this Termination and Release.

     SECTION 7.7 COUNTERPARTS. This Termination and Release may be executed in
two or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute a single agreement.

     SECTION 7.8 THIRD PARTY BENEFICIARIES. Except as specifically provided
herein, this Termination and Release is not intended to confer upon any
non-Party rights or remedies hereunder.

     SECTION 7.9 PRESS RELEASES. In connection with the execution of this
Termination and Release, P&U and InSite agree that InSite will issue a press
release set forth in Exhibit A attached hereto (the "Termination Release"). Once
the Termination Release has been issued, the contents of the release can be
re-released or re-disclosed by either party at any time. Except as permitted by
this Section 7.9, P&U and InSite agree not to make any disclosures, issue any
statements or otherwise cause to be disclosed any information related to the
ISV-900 Project Agreement, the Credit Agreement or the termination of such
agreements without the prior written consent of the other, except as may be
required by law or, in the case of InSite, in connection with the negotiation of
financing, joint venture, merger, acquisition or reorganization transactions
with third parties pursuant to a confidentiality or non-disclosure agreement.

     SECTION 7.10 FURTHER ASSURANCES. Each Party shall execute and deliver such
additional instruments and other documents and use all commercially reasonable
efforts to take or cause to be taken, all actions and to do, or cause to be
done, all things necessary under applicable law to consummate the transactions
and termination contemplated hereby.

     SECTION 7.11 ASSIGNMENT. This Termination and Release shall be binding upon
the successors and assigns of the Parties. This Termination and Release shall
not be assigned by either Party without the prior written consent of the other
Party; provided, however, that this Termination and Release may be assigned by
P&U to any of its Affiliates and either party may assign this Termination and
Release to any third party if such party acquires more than fifty percent (50%)
of the outstanding voting stock of such party or all or substantially all of the
assets of such party.

                                       8
<PAGE>   9

     SECTION 7.12 REPRESENTATIONS AND WARRANTIES.

          (a)  Each of the Parties severally represents and warrants (as to
     itself only) as follows: (i) such party has all the requisite power and
     authority to enter into this Agreement, and (ii) this Agreement will
     constitute, when executed, the valid and binding obligation of such party
     enforceable against such party in accordance with its terms.

          (b)  Each Party represents and warrants that it has not voluntarily or
     involuntarily transferred, conveyed, pledged, assigned or made any other
     disposition of any rights, interest, or causes of action relating to the
     ISV 900 Project Agreement.

     IN WITNESS WHEREOF, the parties hereto have each caused this Termination
and Release to be duly executed as of the date first above written.

INSITE VISION INCORPORATED

By: /s/  S. Kumar Chandrasekaran, Ph.D.
    -----------------------------------
Name: S. Kumar Chandrasekaran, Ph.D.
Title: CEO and Chairman of the Board

PHARMACIA & UPJOHN AB

By: Per-Olof Andersson
    -----------------------------
Name: Per-Olof Andersson
Title: VP Exploratory Development

By:
    -----------------------------
Name:
Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]